Ind-Swift Laboratories, a company in the Pharmaceuticals industry, reported revenue of ₹240 crore and net profit of ₹34 crore for the September 2026 quarter.
Ind-Swift Laboratories (NSE: INDSWFTLAB) closed at ₹317.05 on 20 Nov 2026, up 232.7% over the past year. Its market capitalisation is ₹2,757 crore and it trades at 30.1 times earnings.
Incorporated in 1995, Ind-Swift Laboratories Ltd is a pharmaceutical company focused on finished dosage formulations (FDF). Co. manufactures tablets, capsules, ointments, injectables, liquids and dry syrups across therapies including gynaecology, paediatrics, cardiology, diabetology and dermatology. Operations span domestic formulations and international markets through own brands, contract manufacturing and out-licensing.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.